US Court Says J&J Must Face Majority Of Purchasers’ Remicade Antitrust Suit

Purchasers of the Remicade infliximab brand in the US have accused Johnson & Johnson of an antitrust scheme effectively precluding infliximab biosimilars from competing. A US court says the originator must defend itself against the allegations, adding weight to Pfizer’s cause.